Polycystic Ovarian Syndrome Treatment Market by Drug Class (Insulin Sensitizing Agent, Oral Contraceptive, Antiandrogens, Anti-Obesity Drugs, and Others), and Distribution Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, and Online Providers): Global Opportunity Analysis and Industry Forecast, 20192026
- Published Date: 2020-10-06
- Report ID: 1386
- Pages: 217
-
Format:
The global polycystic ovarian syndrome treatment market was valued at $2,902 million in 2018, and is projected to reach $4,184 million by 2026, registering a CAGR of 4.7% from 2019 to 2026.
Polycystic ovary syndrome or PCOS is a hormonal disorder that is common among women of childbearing age. PCOS causes infrequent or prolonged menstrual cycle or excess male hormone levels. Presently, there is no cure for PCOS, however, medications are used to regulate menstrual cycle and manage symptoms of PCOS.
The polycystic ovarian syndrome treatment market is expected to experience a significant growth during the forecast period, owing to increase in prevalence of PCOS, rise in awareness among the patient population about PCOS, and increase in popularity of combination therapy drives the market growth. In addition, easy accessibility to PCOS therapeutics, rise in demand for PCOS medication, and technological advancements for detection of PCOS influence the market growth. However, lack of approved therapeutics and unknown etiology and pathophysiology of PCOS is anticipated to hamper the market growth.
The global polycystic ovarian syndrome treatment market is segmented on the basis of drug class, distribution channel, and region. Based on drug class, it is classified as insulin sensitizing agent, oral contraceptive, antiandrogens, anti-obesity drugs, and others. According to distribution channel, it is categorized as hospital pharmacies, drug stores & retail pharmacies, and online providers . Region wise, it is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Drug Class
Insulin Sensitizing Agent
Oral Contraceptive
Antiandrogens
Anti-Obesity Drugs
Others
By Distribution Channel
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Providers
By Region
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
Allergan plc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Johnson and Johnson
Mylan N.V.
Novartis AG
Pfizer Inc.
SANOFI
Teva Pharmaceutical Industries
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
Merck KGaA
Ferring BV
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.3.1. List of Key Players Profiled In The Report
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Key Findings
2.2.1. Top Investment Pockets
2.2.2. Market Player Positioning, 2018
2.3. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Forces Shaping Polycystic Ovarian Syndrome Treatment Industry/Market
3.2.1. Moderate Power of Suppliers
3.2.2. High Threat of New Entrants
3.2.3. High Threat of Substitution
3.2.4. Moderate Competitive Rivalry
3.2.5. Moderate Bargaining Power of Buyers
3.3. Market Dynamics
3.3.1. Drivers
3.3.1.1. Increase In Prevalence of Pcos
3.3.1.2. Increase In Number of Pipeline Drugs
3.3.1.3. Surge In Healthcare Expenditure Worldwide
3.3.2. Restraint
3.3.2.1. Lack of Approved Therapeutics For Treatment of Pcos
3.3.3. Opportunities
3.3.3.1. Growth Opportunities In Emerging Markets
3.3.3.2. Higher Number of Unmet Needs For Treatment of Pcos
3.3.4. Impact Analysis
Chapter 4: Polycystic Ovarian Syndrome Treatment Market, By Drug Class
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Insulin Sensitizing Agent
4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis, By Country
4.3. Oral Contraceptive
4.3.1. Key Market Trends And Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis, By Country
4.4. Antiandrogens
4.4.1. Key Market Trends And Opportunities
4.4.2. Market Size And Forecast, By Region
4.4.3. Market Analysis, By Country
4.5. Anti-Obesity Drugs
4.5.1. Key Market Trends And Opportunities
4.5.2. Market Size And Forecast, By Region
4.5.3. Market Analysis, By Country
4.6. Others
4.6.1. Key Market Trends And Opportunities
4.6.2. Market Size And Forecast, By Region
4.6.3. Market Analysis, By Country
Chapter 5: Polycystic Ovarian Syndrome Treatment Market, By End User
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Hospitals Pharmacies
5.2.1. Market Size And Forecast
5.2.2. Market Analysis, By Country
5.3. Drug Stores And Retail Pharmacies
5.3.1. Market Size And Forecast
5.3.2. Market Analysis, By Country
5.4. Online Pharmacies
5.4.1. Market Size And Forecast
5.4.2. Market Analysis, By Country
Chapter 6: Polycystic Ovarian Syndrome Treatment Market, By Region
6.1. Overview
6.1.1. Market Size And Forecast
6.2. North America
6.2.1. Key Market Trends, Growth Factors, And Opportunities
6.2.2. Market Size And Forecast, By Country
6.2.2.1. U.S.
6.2.2.1.1. U.S. Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.2.2.1.2. U.S. Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.2.2.2. Canada
6.2.2.2.1. Canada Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.2.2.2.2. Canada Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.2.2.3. Mexico
6.2.2.3.1. Mexico Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.2.2.3.2. Mexico Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.2.3. North America Market Size And Forecast, By Drug Class
6.2.4. North America Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.3. Europe
6.3.1. Key Market Trends, Growth Factors, And Opportunities
6.3.2. Market Size And Forecast, By Country
6.3.2.1. Germany
6.3.2.1.1. Germany Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.3.2.1.2. Germany Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.3.2.2. France
6.3.2.2.1. France Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.3.2.2.2. France Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.3.2.3. Uk
6.3.2.3.1. Uk Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.3.2.3.2. Uk Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.3.2.4. Italy
6.3.2.4.1. Italy Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.3.2.4.2. Italy Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.3.2.5. Spain
6.3.2.5.1. Spain Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.3.2.5.2. Spain Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.3.2.6.2. Rest of Europe Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.3.3. Europe Market Size And Forecast, By Drug Class
6.3.4. Europe Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.4. Asia-Pacific
6.4.1. Key Market Trends, Growth Factors, And Opportunities
6.4.2. Market Size And Forecast, By Country
6.4.2.1. Japan
6.4.2.1.1. Japan Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.4.2.1.2. Japan Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.4.2.2. China
6.4.2.2.1. China Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.4.2.2.2. China Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.4.2.3. Australia
6.4.2.3.1. Australia Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.4.2.3.2. Australia Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.4.2.4. India
6.4.2.4.1. India Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.4.2.4.2. India Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.4.2.5. South Korea
6.4.2.5.1. South Korea Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.4.2.5.2. South Korea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.4.2.6.2. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.4.3. Asia-Pacific Market Size And Forecast, By Drug Class
6.4.4. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.5. Lamea
6.5.1. Key Market Trends, Growth Factors, And Opportunities
6.5.2. Market Size And Forecast, By Country
6.5.2.1. Brazil
6.5.2.1.1. Brazil Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.5.2.1.2. Brazil Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.5.2.2.2. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.5.2.3. South Africa
6.5.2.3.1. South Africa Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.5.2.3.2. South Africa Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.5.2.4. Rest of Lamea
6.5.2.4.1. Rest of Lamea Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.5.2.4.2. Rest of Lamea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.5.3. Lamea Market Size And Forecast, By Drug Class
6.5.4. Lamea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
Chapter 7: Company Profiles
7.1. Allergan Plc
7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance
7.2. Astrazeneca Plc
7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.2.5. Business Performance
7.3. Bayer Ag.
7.3.1. Company Overview
7.3.2. Operating Business Segments
7.3.3. Product Portfolio
7.3.4. Business Performance
7.4. Bristol-Myers Squibb Company
7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance
7.5. Johnson And Johnson
7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance
7.6. Mylan N.V
7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance
7.7. Novartis Ag
7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.7.5. Business Performance
7.8. Pfizer Inc.
7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.8.5. Business Performance
7.9. Sanofi
7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.9.5. Business Performance
7.10. Teva Pharmaceutical Industries
7.10.1. Company Overview
7.10.2. Operating Business Segments
7.10.3. Product Portfolio
7.10.4. Business Performance
7.10.5. Key Strategic Moves And Developments
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
